Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study) was written by Lu, Bin;Zhang, Ling;Wang, Jiangbin;Wang, Bangmao;Zou, Xiaoping;Fei, Guijun;Chen, Dongfeng;Wang, Xuehong;Wu, Bin;Zou, Duowu. And the article was included in Journal of Gastroenterology and Hepatology in 2018.COA of Formula: C18H20N3NaO3S The following contents are mentioned in the article:
Aim : Empirical proton pump inhibitor (PPI) treatment is recommended as a diagnostic indicator for gastroesophageal reflux disease (GERD) and as a therapy for symptomatic control, with responses generally seen within 4 wk. However, there are no real-world data assessing the effectiveness of short-term empirical treatment with PPIs in patients with GERD in China. Methods : The ENLIGHT study was a multicenter, prospective, observational study conducted in China. Adult patients aged between 18 and 65 years of age, with a gastroesophageal reflux disease questionnaire score of 鈮?8, prescribed empirical PPI treatment by their physicians and with no planned endoscopy were eligible to participate. Statistical analyses were primarily descriptive. Results : Overall, 987 patients were eligible to participate and were included in the full anal. set (FAS); 707 patients were included in the per protocol set. In the FAS, esomeprazole was received by 57.1% of patients and was the most commonly used PPI. After 4-wk treatment, 71.1% of patients were considered responders to PPI. The response rate at the end of 2-wk PPI treatment reached 57.0% (95% CI, 52.5% to 61.7%). The median time to response was 13 days (95% CI, 12 to 15). Response rates at 2 and 4 wk of the per protocol set were similar to those of the FAS. Conclusions : Short-term empirical PPI treatment can provide an effective relief of GERD symptoms in most Chinese patients in real-world practice. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6COA of Formula: C18H20N3NaO3S).
Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.COA of Formula: C18H20N3NaO3S
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem